| scholarly article | Q13442814 |
| P2093 | author name string | Peter Goldstraw | |
| George Ladas | |||
| John E. Pilling | |||
| Michael E. Dusmet | |||
| P2860 | cites work | Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems | Q24679305 |
| The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions | Q33990067 | ||
| Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients | Q34485292 | ||
| The management of malignant pleural mesothelioma; single centre experience in 10 years | Q34762280 | ||
| Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer | Q36648454 | ||
| The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases | Q36695381 | ||
| The MARS trial: mesothelioma and radical surgery | Q38479929 | ||
| Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients | Q39417450 | ||
| Treating malignant pleural effusions cost consciously | Q40872319 | ||
| Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease | Q41713592 | ||
| Management of recurrent malignant pleural effusions. The complementary role talc pleurodesis and pleuroperitoneal shunting | Q42674991 | ||
| Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study | Q44219006 | ||
| Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series | Q46671176 | ||
| Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. | Q51336566 | ||
| Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials | Q64127031 | ||
| Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases | Q72562232 | ||
| Early and late mortality after pleurodesis for malignant pleural effusion | Q74464178 | ||
| Malignancy metastatic to the pleura | Q74730332 | ||
| Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma | Q79447263 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1544-1550 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Prognostic factors for survival after surgical palliation of malignant pleural effusion | |
| Prognostic Factors for Survival after Surgical Palliation of Malignant Pleural Effusion | |||
| P478 | volume | 5 |
| Q91725968 | Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, r |
| Q64326784 | Contemporary best practice in the management of malignant pleural effusion |
| Q46481901 | Diagnosis and management of malignant pleural effusions: state of the art in 2017. |
| Q37090789 | Inflammation in malignant mesothelioma - friend or foe? |
| Q47713836 | Malignant Pleural Effusions: Mistletoe Spray Instead of Talc Poudrage? |
| Q33871571 | Malignant pleural mesothelioma: predictors and staging |
| Q36870952 | Mortality among patients with pleural effusion undergoing thoracentesis |
| Q52650848 | Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. |
| Q28830889 | Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
| Q26858948 | Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions |
| Q37872322 | Pleural controversy: pleurodesis versus indwelling pleural catheters for malignant effusions |
| Q34608340 | Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. |
| Q64944719 | Predictors of survival in non-small cell lung cancer patients with pleural effusion undergoing thoracoscopy. |
| Q37060372 | Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion |
| Q41251928 | Prognostic Factors of 30-Day Mortality After Palliative Procedures in Patients with Malignant Pleural Effusion |
| Q40987505 | Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status? |
| Q42000248 | Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma |
| Q46847002 | Surgical and non-surgical management of malignant pleural effusions. |
| Q48354741 | The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions |
Search more.